686
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Prognostic factors for pure ovarian immature teratoma and the role of adjuvant chemotherapy in stage I diseases

ORCID Icon, , , , , & show all
Article: 2273984 | Received 28 May 2023, Accepted 18 Oct 2023, Published online: 01 Nov 2023

Figures & data

Table 1. Clinical characteristics of POIT patients in the overall cohort (N = 155).

Table 2. Management and survival outcomes in POIT patients of overall cohort (N = 155).

Figure 1. (A) The Kaplan-Meier (log-rank test) curves showed the RFS and DSS rates in this overall POIT cohort. (B) POIT patients with positive postoperative TM had a significantly higher risk of recurrence compared with those who had negative postoperative TM. (C) FIGO stage II-IV significantly increased the mortality risk in POIT patients compared with stage I. (D) The 5-year RFS and DSS rates in stage I POIT except IA G1 subgroup were 88.8% and 99.0%, respectively. (E) A significant difference in RFS rate was noted based on the postoperative TM level (negative vs. positive) in stage I POIT patients except IA G1. (F) Patients who received adjuvant chemotherapy showed significantly better RFS compared with those with active surveillance in POIT of stage IA G2-G3 and IB-IC of any grade.

Figure 1. (A) The Kaplan-Meier (log-rank test) curves showed the RFS and DSS rates in this overall POIT cohort. (B) POIT patients with positive postoperative TM had a significantly higher risk of recurrence compared with those who had negative postoperative TM. (C) FIGO stage II-IV significantly increased the mortality risk in POIT patients compared with stage I. (D) The 5-year RFS and DSS rates in stage I POIT except IA G1 subgroup were 88.8% and 99.0%, respectively. (E) A significant difference in RFS rate was noted based on the postoperative TM level (negative vs. positive) in stage I POIT patients except IA G1. (F) Patients who received adjuvant chemotherapy showed significantly better RFS compared with those with active surveillance in POIT of stage IA G2-G3 and IB-IC of any grade.

Table 3. Clinical characteristics of patients with stage I POIT except IA G1 subgroup (N = 110).

Figure 2. (A–C) Tumor grades (a), surgical options (B), and incomplete surgical staging (C) did not significantly affect the RFS in stage I POIT excluded IA G1. (D) Adjuvant chemotherapy did not significantly improve the DSS rate compared with active surveillance in stage I POIT except IA G1.

Figure 2. (A–C) Tumor grades (a), surgical options (B), and incomplete surgical staging (C) did not significantly affect the RFS in stage I POIT excluded IA G1. (D) Adjuvant chemotherapy did not significantly improve the DSS rate compared with active surveillance in stage I POIT except IA G1.
Supplemental material

Supplemental Material

Download Zip (137 KB)

Data availability statement

All data generated or analyzed during this study are included in this published article and the supplementary information files. The datasets used and/or analyzed during the current study can be obtained from the corresponding author upon reasonable request.